Clinical Trials Logo

Malignant Solid Tumour clinical trials

View clinical trials related to Malignant Solid Tumour.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT02923466 Completed - Clinical trials for Malignant Solid Tumour

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

Start date: April 17, 2017
Phase: Phase 1
Study type: Interventional

This is a three-part open label phase 1 study designed to determine the safety profile, MTD, PK and tumor and biomarker response after IT or IV administration of a single dose of VSV-IFNβ-NIS, or combined IT followed by IV VSV-IFNβ-NIS, with or without IV avelumab every two weeks, in patients with refractory advanced/metastatic solid tumors.

NCT ID: NCT02857920 Completed - Clinical trials for Malignant Solid Tumour

Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

Start date: August 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is the safety and efficacy of Bevacizumab plus allogeneic natural killer (NK) immunotherapy to many kinds of recurrent solid tumors.

NCT ID: NCT02853903 Completed - Clinical trials for Malignant Solid Tumour

Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors

Start date: July 1, 2016
Phase: Phase 2
Study type: Interventional

The aim of this study is the efficacy of autogenic and allogenic natural killer (NK) immunotherapy on recurrent solid tumors.

NCT ID: NCT02843204 Completed - Clinical trials for Malignant Solid Tumour

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Start date: July 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is the safety and efficacy of anti-PD-1 plus NK immunotherapy to multiple solid tumors.

NCT ID: NCT02786628 Completed - Clinical trials for Hematologic Malignancies

Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation

Start date: February 2016
Phase:
Study type: Observational

The primary objective of this study is to assess the feasibility of a multi-institutional study that collects cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or transplant), followed by collection of patient generated health data (wearable activity monitors and patient reported outcomes) for the subsequent month. In addition to demonstrating feasibility, the study looks to generate preliminary data that supports the capacity of physical performance testing and patient-generated health data to complement clinician-rated performance status in patients receiving chemotherapy.

NCT ID: NCT01951846 Completed - Clinical trials for Malignant Solid Tumour

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Start date: November 2002
Phase: Phase 1
Study type: Interventional

The primary objective of this study was to determine the maximum tolerated dose (MTD) of BIBF 1120 in patients with solid tumours by the monitoring of drug-related adverse events. Secondary objectives were the evaluation of safety, efficacy, pharmacokinetics, and pharmacodynamics.

NCT ID: NCT01721148 Completed - Clinical trials for Malignant Solid Tumour

A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours

Start date: October 2012
Phase: Phase 1
Study type: Interventional

There is a great need for new therapies for carcinomas that have progressed on or not responded to current therapy. There are no approved Met targeted agents in standard clinical use. In the population of subjects with advanced carcinomas that are unresponsive to standard of care, and based on the relatively safe, reversible and monitorable toxicity profile of ASLAN002 in non clinical studies, the potential for benefit from ASLAN002 outweighs the potential risks for toxicity. The purpose of this study is to identify the maximum tolerated dose of ASLAN002 in subjects with advanced or metastatic solid tumours, as well as to define the overall safety profile of ASLAN002.

NCT ID: NCT01618136 Completed - Ovarian Cancer Clinical Trials

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Start date: January 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Overall Design: This is a multicenter, open-label, Phase 1/2 study which will be conducted in three arms (as described below). Each arm will be conducted in two parts: a Phase 1 part which will include dose escalation and a Phase 2 part which will include four cohorts in specific disease indications. Phase 1 will also include a food effect study of E7449 as a single agent. Once the MTD in the Phase 1 single agent arm and the Phase 1 combination arms of this study has been achieved, the sponsor will submit the relevant safety information and recommended Phase 2 dose to the IRB/Health Authorities. Arm 1: E7449 will be administered as a single agent. Arm 2: E7449 will be administered in combination with TMZ. Arm 3: E7449 will be administered in combination with carboplatin and paclitaxel

NCT ID: NCT01611857 Completed - Clinical trials for Gastroesophageal Cancer

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

Start date: July 2012
Phase: Phase 1/Phase 2
Study type: Interventional

We propose a Phase I trial of Tivantinib plus FOLFOX for the treatment of patients with advanced solid tumors followed by a Phase II portion for patients with first-line metastatic GE cancer. We hypothesize that the response rate (RR) will be improved from 45% to at least 65% under this regimen.

NCT ID: NCT01598129 Completed - Clinical trials for Malignant Solid Tumour

ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers

Start date: April 2012
Phase: Phase 1
Study type: Interventional

The purpose of the study is to investigate the safety and the recommended dose for later use of an oncolytic adenovirus CGTG-102 in combination with low-dose oral cyclophosphamide in the treatment of advanced cancers.